MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijpx.2026.100673

Медицинская библиотека · International journal of pharmaceutics: X · 2026

Triptolide-loaded MSC membrane nanoparticles with enhanced pulmonary accumulation for the treatment of acute lung injury: from network pharmacology to experimental validation.

Liu Jiahao, Zhao Yue, Zhuang Yixin, Zhou Bowen, Sun Xuerong, Wei Ning, Zeng Xianglan, Li Jiaying, Liu Huihui, Fan Yinqiang, Wang Xin, Jin Hua

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Acute lung injury (ALI) and its severe form acute respiratory distress syndrome (ARDS) are critical conditions with few effective therapies. Triptolide (TPL), a bioactive compound from Tripterygium wilfordii, exhibits potent anti-inflammatory effects but its clinical use is restricted by poor solubility, rapid clearance, and hepatotoxicity. Using network pharmacology and molecular docking as hypothesis-generating approaches, we prioritized NLRP3 inflammasome activation as a key candidate pathway mediating the therapeutic effects of TPL against ALI. Based on this, we developed mesenchymal stem cell membrane-coated TPL-loaded biomimetic nanoparticles (CM@TPL-NPs) comprising a PLGA core loaded with TPL and coated with mesenchymal stem cell membranes. This coating improved biocompatibility, reduced hepatic sequestration, and enabled preferential lung accumulation, while retaining inherent anti-inflammatory activity. CM@TPL-NPs showed favorable physicochemical properties, sustained release, and improved biocompatibility. Mechanistically, they suppressed NLRP3 inflammasome activation in LPS-stimulated macrophages, while preserving endothelial barrier integrity. In a murine ALI model, both intravenous and intranasal CM@TPL-NPs administration reduced inflammation, cytokine levels, oxidative stress, and histopathological damage. Intranasal (IN) instillation demonstrated enhanced pulmonary accumulation and therapeutic efficacy, positioning it as a promising non-invasive strategy. Importantly, the nanoformulation significantly reduced hepatotoxicity compared with free TPL. Overall, CM@TPL-NPs provide a potent, lung-accumulating platform for ALI therapy via modulation of the NLRP3 inflammasome, supporting further preclinical investigation.

Для цитирования: Liu Jiahao, Zhao Yue, Zhuang Yixin, Zhou Bowen, Sun Xuerong, Wei Ning, Zeng Xianglan, Li Jiaying, Liu Huihui, Fan Yinqiang, Wang Xin, Jin Hua. Triptolide-loaded MSC membrane nanoparticles with enhanced pulmonary accumulation for the treatment of acute lung injury: from network pharmacology to experimental validation.. International journal of pharmaceutics: X. 2026. DOI: 10.1016/j.ijpx.2026.100673.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.